EU/3/12/1098:

Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor

Overview

On 24 January 2013, orphan designation (EU/3/12/1098) was granted by the European Commission to Enpharma, United Kingdom, for encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor for treatment of retinitis pigmentosa.

The sponsor's address was updated in May 2018.

The sponsor’s address was updated in October 2020.

The sponsorship was transferred to Le4d Global Regulatory Science Limited, Ireland in December 2020.

Key facts

Active substance
Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor
Intented use
Treatment of retinitis pigmentosa
Date of designation
24/01/2013
Orphan designation status
Positive
EU designation number
EU/3/12/1098

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Le4d Global Regulatory Science Limited
1st Floor
6 Lapp's Quay
Cork T12 VY7W
Co. Cork
Ireland
Tel. +447595963748
E-mail: zubair.le4d@hotmail.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating